Evan David Seigerman
Stock Analyst at BMO Capital
(3.53)
# 938
Out of 5,147 analysts
55
Total ratings
54.17%
Success rate
5.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Maintains: Outperform | $120 → $100 | $66.62 | +50.11% | 2 | Feb 17, 2026 | |
| MRK Merck & Co. | Upgrades: Outperform | $82 → $130 | $123.82 | +4.99% | 5 | Dec 18, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $725 → $850 | $781.67 | +8.74% | 9 | Dec 4, 2025 | |
| AMGN Amgen | Maintains: Outperform | $335 → $372 | $388.16 | -4.16% | 5 | Dec 3, 2025 | |
| NVO Novo Nordisk | Maintains: Market Perform | $50 → $46 | $37.45 | +22.83% | 8 | Nov 25, 2025 | |
| REPL Replimune Group | Upgrades: Market Perform | $2 → $11 | $7.65 | +43.79% | 5 | Nov 3, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $215 → $240 | $232.08 | +3.41% | 8 | Sep 12, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $23.49 | +10.69% | 2 | Jun 12, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $24.56 | +14.01% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $13.27 | -24.64% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $62.98 | +58.78% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $27.65 | +30.20% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $5.25 | -42.86% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $1,051.99 | -62.36% | 1 | Sep 6, 2022 |
Disc Medicine
Feb 17, 2026
Maintains: Outperform
Price Target: $120 → $100
Current: $66.62
Upside: +50.11%
Merck & Co.
Dec 18, 2025
Upgrades: Outperform
Price Target: $82 → $130
Current: $123.82
Upside: +4.99%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Outperform
Price Target: $725 → $850
Current: $781.67
Upside: +8.74%
Amgen
Dec 3, 2025
Maintains: Outperform
Price Target: $335 → $372
Current: $388.16
Upside: -4.16%
Novo Nordisk
Nov 25, 2025
Maintains: Market Perform
Price Target: $50 → $46
Current: $37.45
Upside: +22.83%
Replimune Group
Nov 3, 2025
Upgrades: Market Perform
Price Target: $2 → $11
Current: $7.65
Upside: +43.79%
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215 → $240
Current: $232.08
Upside: +3.41%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $23.49
Upside: +10.69%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $24.56
Upside: +14.01%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $13.27
Upside: -24.64%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $62.98
Upside: +58.78%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $27.65
Upside: +30.20%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $5.25
Upside: -42.86%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $1,051.99
Upside: -62.36%